CU23963B1 - Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas - Google Patents

Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas

Info

Publication number
CU23963B1
CU23963B1 CU2011000146A CU20110146A CU23963B1 CU 23963 B1 CU23963 B1 CU 23963B1 CU 2011000146 A CU2011000146 A CU 2011000146A CU 20110146 A CU20110146 A CU 20110146A CU 23963 B1 CU23963 B1 CU 23963B1
Authority
CU
Cuba
Prior art keywords
interferons
derivatives
treatment
type
pharmaceutical compositions
Prior art date
Application number
CU2011000146A
Other languages
English (en)
Spanish (es)
Other versions
CU20110146A7 (es
Inventor
Rol Giselle Pentón
Arzuaga Alexey Llopiz
Prida Javier Marín
Arias Eduardo Pentón
Jiménez Efraín Rodríguez
Lasa Alexis Musacchio
Pérez Vladimir Armando Besada
Andreu Gilberto Lázaro Pardo
López Luis Javier González
Fuentes Nancy Pavón
Nieto Gerardo Enrique Guillén
Saura Pedro Antonio López
Original Assignee
Ct De Ingeniería Genética Y Biotecnología
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Ingeniería Genética Y Biotecnología filed Critical Ct De Ingeniería Genética Y Biotecnología
Priority to CU2011000146A priority Critical patent/CU23963B1/es
Priority to AU2012280776A priority patent/AU2012280776B2/en
Priority to KR1020147002552A priority patent/KR101987978B1/ko
Priority to BR112013033970-5A priority patent/BR112013033970B1/pt
Priority to ES12743356.3T priority patent/ES2601887T3/es
Priority to RU2014103246/04A priority patent/RU2569302C2/ru
Priority to PCT/CU2012/000003 priority patent/WO2013004203A1/es
Priority to MX2013015206A priority patent/MX345534B/es
Priority to JP2014517444A priority patent/JP6023803B2/ja
Priority to DK12743356.3T priority patent/DK2733149T3/en
Priority to CA2838496A priority patent/CA2838496C/en
Priority to CN201280032375.5A priority patent/CN103649106B/zh
Priority to US14/127,369 priority patent/US9518085B2/en
Priority to EP12743356.3A priority patent/EP2733149B9/en
Priority to SI201230756A priority patent/SI2733149T1/sl
Priority to IN510CHN2014 priority patent/IN2014CN00510A/en
Priority to ARP120102397A priority patent/AR087034A1/es
Publication of CU20110146A7 publication Critical patent/CU20110146A7/es
Publication of CU23963B1 publication Critical patent/CU23963B1/es
Priority to ZA2013/09554A priority patent/ZA201309554B/en
Priority to US15/348,451 priority patent/US20170119733A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Alternative & Traditional Medicine (AREA)
CU2011000146A 2011-07-01 2011-07-01 Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas CU23963B1 (es)

Priority Applications (19)

Application Number Priority Date Filing Date Title
CU2011000146A CU23963B1 (es) 2011-07-01 2011-07-01 Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas
DK12743356.3T DK2733149T3 (en) 2011-07-01 2012-06-29 RELATIONS AND PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF NEURODEGENERATIVE and ischemic BRAIN DISEASES
CA2838496A CA2838496C (en) 2011-07-01 2012-06-29 Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
BR112013033970-5A BR112013033970B1 (pt) 2011-07-01 2012-06-29 Composição farmacêutica de peptídeos cromogênicos (pcb-aa), combinação dos mesmos e ficocianobilina, bem como uso da referida combinação
ES12743356.3T ES2601887T3 (es) 2011-07-01 2012-06-29 Compuestos y combinaciones farmacéuticas para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas
RU2014103246/04A RU2569302C2 (ru) 2011-07-01 2012-06-29 Соединения и фармацевтические комбинации для лечения нейродегенеративных и ишемических болезней мозга
PCT/CU2012/000003 WO2013004203A1 (es) 2011-07-01 2012-06-29 Compuestos y combinaciones farmacéuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas
MX2013015206A MX345534B (es) 2011-07-01 2012-06-29 Compuestos y combinaciones farmaceuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas.
JP2014517444A JP6023803B2 (ja) 2011-07-01 2012-06-29 神経変性及び虚血性脳疾患を処置するための化合物及び薬学的組合せ
AU2012280776A AU2012280776B2 (en) 2011-07-01 2012-06-29 Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
KR1020147002552A KR101987978B1 (ko) 2011-07-01 2012-06-29 신경퇴행성 및 허혈성 뇌질환 치료를 위한 화합물 및 약제학적 조성물
CN201280032375.5A CN103649106B (zh) 2011-07-01 2012-06-29 用于治疗神经退行性和缺血性脑疾病的化合物和药学组合
US14/127,369 US9518085B2 (en) 2011-07-01 2012-06-29 Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
EP12743356.3A EP2733149B9 (en) 2011-07-01 2012-06-29 Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
SI201230756A SI2733149T1 (sl) 2011-07-01 2012-06-29 Spojine in farmacevtske kombinacije za zdravljenje nevrodegenerativnih in ishemičnih bolezni možganov
IN510CHN2014 IN2014CN00510A (forum.php) 2011-07-01 2012-06-29
ARP120102397A AR087034A1 (es) 2011-07-01 2012-07-02 Compuestos y combinaciones farmaceuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas
ZA2013/09554A ZA201309554B (en) 2011-07-01 2013-12-18 Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
US15/348,451 US20170119733A1 (en) 2011-07-01 2016-11-10 Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2011000146A CU23963B1 (es) 2011-07-01 2011-07-01 Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas

Publications (2)

Publication Number Publication Date
CU20110146A7 CU20110146A7 (es) 2013-02-26
CU23963B1 true CU23963B1 (es) 2013-12-11

Family

ID=46614264

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000146A CU23963B1 (es) 2011-07-01 2011-07-01 Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas

Country Status (18)

Country Link
US (2) US9518085B2 (forum.php)
EP (1) EP2733149B9 (forum.php)
JP (1) JP6023803B2 (forum.php)
KR (1) KR101987978B1 (forum.php)
CN (1) CN103649106B (forum.php)
AR (1) AR087034A1 (forum.php)
AU (1) AU2012280776B2 (forum.php)
BR (1) BR112013033970B1 (forum.php)
CA (1) CA2838496C (forum.php)
CU (1) CU23963B1 (forum.php)
DK (1) DK2733149T3 (forum.php)
ES (1) ES2601887T3 (forum.php)
IN (1) IN2014CN00510A (forum.php)
MX (1) MX345534B (forum.php)
RU (1) RU2569302C2 (forum.php)
SI (1) SI2733149T1 (forum.php)
WO (1) WO2013004203A1 (forum.php)
ZA (1) ZA201309554B (forum.php)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183061B2 (en) * 2013-06-25 2019-01-22 Icm (Institut Du Cerveau Et De La Moelle Epiniere) Boosting Treg cells for treating Alzheimer disease and related disorders
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
RU2613765C1 (ru) * 2016-01-26 2017-03-21 Федеральное государственное автономное образовательное учреждение высшего образования "Северо-Восточный федеральный университет им. М.К.Аммосова" Способ лечения спиноцеребеллярной атаксии
CN108752445B (zh) * 2018-06-20 2021-04-30 广东药科大学 一种螺旋藻蛋白的制备工艺及其神经保护用途
KR102152407B1 (ko) * 2019-02-26 2020-09-07 (주)나우코스 스피루리나에서 유래한 파이코시아노블린 및 이의 유도체를 유효성분으로 포함하는 화장료 조성물
KR20210091664A (ko) 2020-01-14 2021-07-22 경북대학교 산학협력단 중간엽 줄기세포 유래 단백질을 포함하는 소뇌성운동실조증의 치료 예후를 예측하기 위한 바이오마커, 및 이를 이용한 소뇌성운동실조증의 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709855A (en) 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
US20040110938A1 (en) * 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
US7025965B1 (en) * 2003-02-12 2006-04-11 Pharma Chemie, Inc. Method of use and dosage composition of bluegreen algae extract for inflammation in animals
EP1608400B1 (en) * 2003-03-28 2010-06-23 Faron Pharmaceuticals OY Elevation of adenosine level by cytokine-induced expression of cd73
CU23581A1 (es) * 2005-10-28 2010-10-30 Ct Ingenieria Genetica Biotech Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer
AU2007264042B2 (en) * 2006-06-27 2012-01-12 Nutratec S.R.L. Alphanizomenon Flos Aquae preparation, extracts and purified components thereof for the treatment of neurological, neurodegenerative and mood disorders
EP3111933B1 (en) * 2006-11-13 2019-09-04 PCB Associates, Inc. Prophylaxis or treatment of glomerulosclerosis

Also Published As

Publication number Publication date
IN2014CN00510A (forum.php) 2015-04-03
BR112013033970A2 (pt) 2017-02-14
RU2014103246A (ru) 2015-08-10
US20170119733A1 (en) 2017-05-04
WO2013004203A1 (es) 2013-01-10
AU2012280776B2 (en) 2016-07-14
SI2733149T1 (sl) 2017-01-31
AU2012280776A1 (en) 2014-01-23
RU2569302C2 (ru) 2015-11-20
MX2013015206A (es) 2014-02-20
KR20140078601A (ko) 2014-06-25
JP2014520764A (ja) 2014-08-25
EP2733149A1 (en) 2014-05-21
EP2733149B1 (en) 2016-09-28
JP6023803B2 (ja) 2016-11-09
CA2838496C (en) 2020-01-07
CN103649106A (zh) 2014-03-19
CU20110146A7 (es) 2013-02-26
AR087034A1 (es) 2014-02-05
CN103649106B (zh) 2016-01-20
ZA201309554B (en) 2014-08-27
EP2733149B9 (en) 2019-05-15
KR101987978B1 (ko) 2019-06-11
DK2733149T3 (en) 2016-11-28
BR112013033970B1 (pt) 2022-10-18
CA2838496A1 (en) 2013-01-10
US20140356319A1 (en) 2014-12-04
US9518085B2 (en) 2016-12-13
ES2601887T3 (es) 2017-02-16
MX345534B (es) 2017-02-03

Similar Documents

Publication Publication Date Title
CU20160087A7 (es) Indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen
PE20151023A1 (es) Triazolopirazinas
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
CR20180232A (es) Macrociclos peptídicos contra acinetobacter baumannii
MX375706B (es) Compuestos de inhibidor de autotaxina.
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
MX2015009269A (es) Composiciones farmaceuticas que comprenden donadores de nitroxilo.
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
CU20110146A7 (es) Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
MX2017003788A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial.
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
UY37622A (es) Derivados de pirazol como inhibidores de bromodominio de la familia bet y su uso en aplicaciones terapéuticas
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
PE20151424A1 (es) Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales
CO2017005766A2 (es) Composiciones farmacéuticas de acción prolongada para hepatitis c
CO2017005767A2 (es) Composiciones de acción prolongada de combinación y procedimientos para hepatitis c
MX2019007950A (es) Inhibidores tripeptidicos de la epoxicetona proteasa.
GT201600190A (es) Compuestos químicos
NI201500172A (es) Composiciones farmacéuticas
UY35989A (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria
ECSP15025357A (es) Formas de dosificación de ruxolitinib de liberación sostenida